BundleHulafe
type: Bundle
node role: treeRoot
id:
  v: BundleHulafe
meta:
  profile:
    v: http://hl7.eu/fhir/ig/pcsp/StructureDefinition/Bundle-eu-pcsp
    l: Bundle-eu-pcsp
identifier:
  system:
    v: http://fhir.ehealth-systems.at/identifier/pcsp-bundle
    l: pcsp-bundle
  value:
    v: hulafe-pcsp-bundle-2025
type:
  v: document
timestamp:
  v: 2025-06-11T07:41:51.868411+00:00
entry:
  full url:
    v: http://hl7.eu/fhir/ig/pcsp/Composition/CompositionHulafe
    l: CompositionHulafe
  resource: CompositionHulafe
entry:
  full url:
    v: http://hl7.eu/fhir/ig/pcsp/Patient/PatientHulafe-1
    l: PatientHulafe-1
  resource: PatientHulafe-1
entry:
  full url:
    v: http://hl7.eu/fhir/ig/pcsp/Condition/PrimaryCancerHulafe-1
    l: PrimaryCancerHulafe-1
  resource: PrimaryCancerHulafe-1
entry:
  full url:
    v: http://hl7.eu/fhir/ig/pcsp/Encounter/EncHulafe-1
    l: EncHulafe-1
  resource: EncHulafe-1
entry:
  full url:
    v: http://hl7.eu/fhir/ig/pcsp/MedicationAdministration/ChemoHulafe-1-Ciclofosfamide
    l: ChemoHulafe-1-Ciclofosfamide
  resource: ChemoHulafe-1-Ciclofosfamide
entry:
  full url:
    v: http://hl7.eu/fhir/ig/pcsp/MedicationAdministration/ChemoHulafe-1-Metotrexato
    l: ChemoHulafe-1-Metotrexato
  resource: ChemoHulafe-1-Metotrexato
entry:
  full url:
    v: http://hl7.eu/fhir/ig/pcsp/MedicationAdministration/ChemoHulafe-1-Vincristina
    l: ChemoHulafe-1-Vincristina
  resource: ChemoHulafe-1-Vincristina
entry:
  full url:
    v: http://hl7.eu/fhir/ig/pcsp/MedicationAdministration/ChemoHulafe-1-Citarabina
    l: ChemoHulafe-1-Citarabina
  resource: ChemoHulafe-1-Citarabina
entry:
  full url:
    v: http://hl7.eu/fhir/ig/pcsp/MedicationStatement/ChemoHulafe-1-corticosteroids
    l: ChemoHulafe-1-corticosteroids
  resource: ChemoHulafe-1-corticosteroids
entry:
  full url:
    v: http://hl7.eu/fhir/ig/pcsp/Observation/ChemoHulafe-1-Ciclofosfamide-dose
    l: ChemoHulafe-1-Ciclofosfamide-dose
  resource: ChemoHulafe-1-Ciclofosfamide-dose
entry:
  full url:
    v: http://hl7.eu/fhir/ig/pcsp/Observation/ChemoHulafe-1-Metotrexato-dose
    l: ChemoHulafe-1-Metotrexato-dose
  resource: ChemoHulafe-1-Metotrexato-dose
entry:
  full url:
    v: http://hl7.eu/fhir/ig/pcsp/Observation/ChemoHulafe-1-Vincristina-dose
    l: ChemoHulafe-1-Vincristina-dose
  resource: ChemoHulafe-1-Vincristina-dose
entry:
  full url:
    v: http://hl7.eu/fhir/ig/pcsp/Observation/ChemoHulafe-1-Citarabina-dose
    l: ChemoHulafe-1-Citarabina-dose
  resource: ChemoHulafe-1-Citarabina-dose
entry:
  full url:
    v: http://hl7.eu/fhir/ig/pcsp/Organization/OrgHulafe-1
    l: OrgHulafe-1
  resource: OrgHulafe-1
entry:
  full url:
    v: http://hl7.eu/fhir/ig/pcsp/Location/ChemoHulafe-1-Location
    l: ChemoHulafe-1-Location
  resource: ChemoHulafe-1-Location
entry:
  full url:
    v: http://hl7.eu/fhir/ig/pcsp/CarePlan/CarePlanExample-1
    l: CarePlanExample-1
  resource: CarePlanExample-1
entry:
  full url:
    v: http://hl7.eu/fhir/ig/pcsp/Observation/ObservationRiskFactor-1
    l: ObservationRiskFactor-1
  resource: ObservationRiskFactor-1
entry:
  full url:
    v: http://hl7.eu/fhir/ig/pcsp/Observation/ObservationRiskFactor-2
    l: ObservationRiskFactor-2
  resource: ObservationRiskFactor-2
entry:
  full url:
    v: http://hl7.eu/fhir/ig/pcsp/Observation/ObservationRiskFactor-3
    l: ObservationRiskFactor-3
  resource: ObservationRiskFactor-3
entry:
  full url:
    v: http://hl7.eu/fhir/ig/pcsp/Observation/ObservationRiskFactor-4
    l: ObservationRiskFactor-4
  resource: ObservationRiskFactor-4
entry:
  full url:
    v: http://hl7.eu/fhir/ig/pcsp/DocumentReference/DocumentReferenceExample-1
    l: DocumentReferenceExample-1
  resource: DocumentReferenceExample-1

CompositionHulafe
type: Composition
id:
  v: CompositionHulafe
meta:
  profile:
    v: http://hl7.eu/fhir/ig/pcsp/StructureDefinition/Composition-surpass-eu-pcsp
    l: Composition-surpass-eu-pcsp
text:
  status:
    v: generated
  div:
    v: Generated Narrative: Composition CompositionHulafe Profile: Composition: Survivor Passport status: Preliminary type: Childhood Cancer Survivor Passport date: 2025-06-11 07:41:51+0000 author: Identifier: test title: Childhood Cancer Survivor Passport
status:
  v: preliminary
type:
  coding:
    system:
      v: http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-generic-eu-pcsp
      l: cs-generic-eu-pcsp
    code:
      v: surpass
subject:
  l: PatientHulafe-1
  reference:
    v: Patient/PatientHulafe-1
date:
  v: 2025-06-11T07:41:51.417033+00:00
author:
  identifier:
    value:
      v: test
title:
  v: Childhood Cancer Survivor Passport
section:
  title:
    v: Cancer Diagnosis and Treatment
  code:
    coding: https://loinc.org/rdf/72135-7
      system:
        v: http://loinc.org
        l: loinc.org
      code:
        v: 72135-7
  text:
    status:
      v: generated
    div:
      v: Primary Cancer Diagnosis and Treatment Summary
  entry:
    l: PrimaryCancerHulafe-1
    reference:
      v: Condition/PrimaryCancerHulafe-1
  section:
    title:
      v: Chemotherapy
    code:
      coding: https://loinc.org/rdf/11486-8
    text:
      status:
        v: generated
      div:
        v: Chemotherapy Treatments
    entry:
      l: ChemoHulafe-1-Ciclofosfamide
      reference:
        v: MedicationAdministration/ChemoHulafe-1-Ciclofosfamide
    entry:
      l: ChemoHulafe-1-Metotrexato
      reference:
        v: MedicationAdministration/ChemoHulafe-1-Metotrexato
    entry:
      l: ChemoHulafe-1-Vincristina
      reference:
        v: MedicationAdministration/ChemoHulafe-1-Vincristina
    entry:
      l: ChemoHulafe-1-Citarabina
      reference:
        v: MedicationAdministration/ChemoHulafe-1-Citarabina
    entry:
      l: ChemoHulafe-1-corticosteroids
      reference:
        v: MedicationStatement/ChemoHulafe-1-corticosteroids
section:
  title:
    v: Care Plan
  code:
    coding: https://loinc.org/rdf/18776-5
      system:
        v: http://loinc.org
        l: loinc.org
      code:
        v: 18776-5
  text:
    status:
      v: generated
    div:
      v: Care Plan
  entry:
    l: CarePlanExample-1
    reference:
      v: CarePlan/CarePlanExample-1

PatientHulafe-1
type: Patient
id:
  v: PatientHulafe-1
meta:
  profile:
    v: http://hl7.eu/fhir/ig/pcsp/StructureDefinition/Patient-eu-pcsp
    l: Patient-eu-pcsp
language:
  v: es-ES
text:
  status:
    v: generated
  div:
    v: Generated Narrative: Patient PatientHulafe-1 Language: es-ES Profile: Patient: PCSP NOMBRE APELLIDO1 APELLIDO2(anonymous) Female, DoB: 2005-07-01 ( urn:oid:2.16.724.4.10.50.200#123456789 (use: official, )) Contact Detail belensmicorr@gggmail.com Language: Spanish (Spain) Patient Mother's Maiden Name APELLIDO2 Patient Birth Place CALLEFALSA123 Valencia Valencia España
extension:
  url:
    v: http://hl7.org/fhir/StructureDefinition/patient-mothersMaidenName
    l: patient-mothersMaidenName
  value: String
    v: APELLIDO2
extension:
  url:
    v: http://hl7.org/fhir/StructureDefinition/patient-birthPlace
    l: patient-birthPlace
  value: Address
    line:
      v: CALLEFALSA123
    city:
      v: Valencia
    state:
      v: Valencia
    country:
      v: España
identifier:
  use:
    v: official
  system:
    v: urn:oid:2.16.724.4.10.50.200
    l: 2.16.724.4.10.50.200
  value:
    v: 123456789
name:
  use:
    v: anonymous
  text:
    v: NOMBRE APELLIDO1 APELLIDO2
  family:
    v: APELLIDO1
  given:
    v: NOMBRE
telecom:
  system:
    v: email
gender:
  v: female
birth date:
  v: 2005-07-01
communication:
  language:
    coding:
      system:
        v: urn:ietf:bcp:47
        l: 47
      code:
        v: es-ES
      display:
        v: Spanish (Spain)

PrimaryCancerHulafe-1
type: Condition
id:
  v: PrimaryCancerHulafe-1
meta:
  profile:
    v: http://hl7.eu/fhir/ig/pcsp/StructureDefinition/Condition-primaryCancer-eu-pcsp
    l: Condition-primaryCancer-eu-pcsp
language:
  v: es-ES
text:
  status:
    v: extensions
  div:
    v: Generated Narrative: Condition PrimaryCancerHulafe-1 Language: es-ES Profile: Condition: Primary Cancer Condition Asserted Date: 2021 Histology-Morphology-Behavior Extension: 8260/3 - Carcinoma papilar de tiroides code: Carcinoma tiroides bodySite: C73.9 subject: NOMBRE APELLIDO1 APELLIDO2(anonymous) Female, DoB: 2005-07-01 ( urn:oid:2.16.724.4.10.50.200#123456789 (use: official, )) encounter: Encounter: status = finished; class = ambulatory (ActCode#AMB) Stages - Summary * pT1a note: Alergia al epitelio de gato
extension:
  url:
    v: http://hl7.org/fhir/StructureDefinition/condition-assertedDate
    l: condition-assertedDate
  value: DateTime
    v: 2021
extension:
  url:
    v: http://hl7.org/fhir/us/mcode/StructureDefinition/mcode-histology-morphology-behavior
    l: mcode-histology-morphology-behavior
  value: CodeableConcept
    coding:
      system:
        v: http://terminology.hl7.org/CodeSystem/icd-o-3
        l: icd-o-3
      code:
        v: 8260/3
      display:
        v: 8260/3 - Carcinoma papilar de tiroides
code:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/v3-NullFlavor
      l: v3-NullFlavor
    code:
      v: UNC
    display:
      v: un-encoded
  text:
    v: Carcinoma tiroides
body site:
  extension:
    url:
      v: http://hl7.eu/fhir/ig/pcsp/StructureDefinition/mcode-laterality-qualifier
      l: mcode-laterality-qualifier
    value: CodeableConcept
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/icd-o-3
      l: icd-o-3
    code:
      v: C73.9
    display:
      v: C73.9 - Tiroides
  text:
    v: C73.9
subject:
  l: PatientHulafe-1
  reference:
    v: Patient/PatientHulafe-1
  type:
    v: Patient
    l: Patient
encounter:
  l: EncHulafe-1
  reference:
    v: Encounter/EncHulafe-1
  type:
    v: Encounter
    l: Encounter
stage:
  summary:
    coding:
      system:
        v: http://terminology.hl7.org/CodeSystem/v3-NullFlavor
        l: v3-NullFlavor
      code:
        v: UNC
      display:
        v: un-encoded
    text:
      v: pT1a
note:
  text:
    v: Alergia al epitelio de gato

EncHulafe-1
type: Encounter
id:
  v: EncHulafe-1
language:
  v: es-ES
text:
  status:
    v: generated
  div:
    v: Generated Narrative: Encounter EncHulafe-1 Language: es-ES status: Finished class: ActCode: AMB (ambulatory) subject: NOMBRE APELLIDO1 APELLIDO2(anonymous) Female, DoB: 2005-07-01 ( urn:oid:2.16.724.4.10.50.200#123456789 (use: official, )) serviceProvider: Organization Hospital Universitari i Politècnic La Fe
status:
  v: finished
class:
  system:
    v: http://terminology.hl7.org/CodeSystem/v3-ActCode
    l: v3-ActCode
  code:
    v: AMB
  display:
    v: ambulatory
subject:
  l: PatientHulafe-1
  reference:
    v: Patient/PatientHulafe-1
  type:
    v: Patient
    l: Patient
service provider:
  l: OrgHulafe-1
  reference:
    v: Organization/OrgHulafe-1
  type:
    v: Organization
    l: Organization

ChemoHulafe-1-Ciclofosfamide
type: MedicationAdministration
id:
  v: ChemoHulafe-1-Ciclofosfamide
meta:
  profile:
    v: http://hl7.eu/fhir/ig/pcsp/StructureDefinition/MedicationAdministration-eu-pcsp
    l: MedicationAdministration-eu-pcsp
text:
  status:
    v: extensions
  div:
    v: Generated Narrative: MedicationAdministration ChemoHulafe-1-Ciclofosfamide Profile: MedicationAdministration: Chemotherapy Act Location: Location Hospital la Fe Resource related information: Observation Cumulative dose received by a patient for a specific drug. status: Completed medication: cyclophosphamide subject: NOMBRE APELLIDO1 APELLIDO2(anonymous) Female, DoB: 2005-07-01 ( urn:oid:2.16.724.4.10.50.200#123456789 (use: official, )) effective: 2012-08-08 --> 2012-10-11 reasonReference: Condition un-encoded
extension:
  url:
    v: http://hl7.eu/fhir/ig/pcsp/StructureDefinition/event-location
    l: event-location
  value: Reference
    l: ChemoHulafe-1-Location
    reference:
      v: Location/ChemoHulafe-1-Location
extension:
  url:
    v: http://hl7.eu/fhir/ig/pcsp/StructureDefinition/resource-relatedInfo
    l: resource-relatedInfo
  value: Reference
    l: ChemoHulafe-1-Ciclofosfamide-dose
    reference:
      v: Observation/ChemoHulafe-1-Ciclofosfamide-dose
status:
  v: completed
medication: CodeableConcept
  coding:
    system:
      v: http://www.whocc.no/atc
      l: atc
    code:
      v: L01AA01
    display:
      v: cyclophosphamide
subject:
  l: PatientHulafe-1
  reference:
    v: Patient/PatientHulafe-1
  type:
    v: Patient
    l: Patient
effective: Period
  start:
    v: 2012-08-08
  end:
    v: 2012-10-11
reason reference:
  l: PrimaryCancerHulafe-1
  reference:
    v: Condition/PrimaryCancerHulafe-1

ChemoHulafe-1-Metotrexato
type: MedicationAdministration
id:
  v: ChemoHulafe-1-Metotrexato
meta:
  profile:
    v: http://hl7.eu/fhir/ig/pcsp/StructureDefinition/MedicationAdministration-eu-pcsp
    l: MedicationAdministration-eu-pcsp
text:
  status:
    v: extensions
  div:
    v: Generated Narrative: MedicationAdministration ChemoHulafe-1-Metotrexato Profile: MedicationAdministration: Chemotherapy Act Location: Location Hospital la Fe Resource related information: Observation Cumulative dose received by a patient for a specific drug. status: Completed medication: methotrexate subject: NOMBRE APELLIDO1 APELLIDO2(anonymous) Female, DoB: 2005-07-01 ( urn:oid:2.16.724.4.10.50.200#123456789 (use: official, )) effective: 2012-08-08 --> 2012-10-11 reasonReference: Condition un-encoded
extension:
  url:
    v: http://hl7.eu/fhir/ig/pcsp/StructureDefinition/event-location
    l: event-location
  value: Reference
    l: ChemoHulafe-1-Location
    reference:
      v: Location/ChemoHulafe-1-Location
extension:
  url:
    v: http://hl7.eu/fhir/ig/pcsp/StructureDefinition/resource-relatedInfo
    l: resource-relatedInfo
  value: Reference
    l: ChemoHulafe-1-Metotrexato-dose
    reference:
      v: Observation/ChemoHulafe-1-Metotrexato-dose
status:
  v: completed
medication: CodeableConcept
  coding:
    system:
      v: http://www.whocc.no/atc
      l: atc
    code:
      v: L01BA01
    display:
      v: methotrexate
subject:
  l: PatientHulafe-1
  reference:
    v: Patient/PatientHulafe-1
  type:
    v: Patient
    l: Patient
effective: Period
  start:
    v: 2012-08-08
  end:
    v: 2012-10-11
reason reference:
  l: PrimaryCancerHulafe-1
  reference:
    v: Condition/PrimaryCancerHulafe-1

ChemoHulafe-1-Vincristina
type: MedicationAdministration
id:
  v: ChemoHulafe-1-Vincristina
meta:
  profile:
    v: http://hl7.eu/fhir/ig/pcsp/StructureDefinition/MedicationAdministration-eu-pcsp
    l: MedicationAdministration-eu-pcsp
text:
  status:
    v: extensions
  div:
    v: Generated Narrative: MedicationAdministration ChemoHulafe-1-Vincristina Profile: MedicationAdministration: Chemotherapy Act Location: Location Hospital la Fe Resource related information: Observation Cumulative dose received by a patient for a specific drug. status: Completed medication: vincristine subject: NOMBRE APELLIDO1 APELLIDO2(anonymous) Female, DoB: 2005-07-01 ( urn:oid:2.16.724.4.10.50.200#123456789 (use: official, )) effective: 2012-08-08 --> 2012-10-11 reasonReference: Condition un-encoded
extension:
  url:
    v: http://hl7.eu/fhir/ig/pcsp/StructureDefinition/event-location
    l: event-location
  value: Reference
    l: ChemoHulafe-1-Location
    reference:
      v: Location/ChemoHulafe-1-Location
extension:
  url:
    v: http://hl7.eu/fhir/ig/pcsp/StructureDefinition/resource-relatedInfo
    l: resource-relatedInfo
  value: Reference
    l: ChemoHulafe-1-Vincristina-dose
    reference:
      v: Observation/ChemoHulafe-1-Vincristina-dose
status:
  v: completed
medication: CodeableConcept
  coding:
    system:
      v: http://www.whocc.no/atc
      l: atc
    code:
      v: L01CA02
    display:
      v: vincristine
subject:
  l: PatientHulafe-1
  reference:
    v: Patient/PatientHulafe-1
  type:
    v: Patient
    l: Patient
effective: Period
  start:
    v: 2012-08-08
  end:
    v: 2012-10-11
reason reference:
  l: PrimaryCancerHulafe-1
  reference:
    v: Condition/PrimaryCancerHulafe-1

ChemoHulafe-1-Citarabina
type: MedicationAdministration
id:
  v: ChemoHulafe-1-Citarabina
meta:
  profile:
    v: http://hl7.eu/fhir/ig/pcsp/StructureDefinition/MedicationAdministration-eu-pcsp
    l: MedicationAdministration-eu-pcsp
text:
  status:
    v: extensions
  div:
    v: Generated Narrative: MedicationAdministration ChemoHulafe-1-Citarabina Profile: MedicationAdministration: Chemotherapy Act Location: Location Hospital la Fe Resource related information: Observation Cumulative dose received by a patient for a specific drug. status: Completed medication: cytarabine subject: NOMBRE APELLIDO1 APELLIDO2(anonymous) Female, DoB: 2005-07-01 ( urn:oid:2.16.724.4.10.50.200#123456789 (use: official, )) effective: 2012-08-08 --> 2012-10-11 reasonReference: Condition un-encoded
extension:
  url:
    v: http://hl7.eu/fhir/ig/pcsp/StructureDefinition/event-location
    l: event-location
  value: Reference
    l: ChemoHulafe-1-Location
    reference:
      v: Location/ChemoHulafe-1-Location
extension:
  url:
    v: http://hl7.eu/fhir/ig/pcsp/StructureDefinition/resource-relatedInfo
    l: resource-relatedInfo
  value: Reference
    l: ChemoHulafe-1-Citarabina-dose
    reference:
      v: Observation/ChemoHulafe-1-Citarabina-dose
status:
  v: completed
medication: CodeableConcept
  coding:
    system:
      v: http://www.whocc.no/atc
      l: atc
    code:
      v: L01BC01
    display:
      v: cytarabine
subject:
  l: PatientHulafe-1
  reference:
    v: Patient/PatientHulafe-1
  type:
    v: Patient
    l: Patient
effective: Period
  start:
    v: 2012-08-08
  end:
    v: 2012-10-11
reason reference:
  l: PrimaryCancerHulafe-1
  reference:
    v: Condition/PrimaryCancerHulafe-1

ChemoHulafe-1-corticosteroids
type: MedicationStatement
id:
  v: ChemoHulafe-1-corticosteroids
meta:
  profile:
    v: http://hl7.eu/fhir/ig/pcsp/StructureDefinition/MedicationStatement-eu-pcsp
    l: MedicationStatement-eu-pcsp
text:
  status:
    v: generated
  div:
    v: Generated Narrative: MedicationStatement ChemoHulafe-1-corticosteroids Profile: MedicationStatement: Chemotherapy status: Not Taken medication: CORTICOSTEROIDS FOR SYSTEMIC USE subject: NOMBRE APELLIDO1 APELLIDO2(anonymous) Female, DoB: 2005-07-01 ( urn:oid:2.16.724.4.10.50.200#123456789 (use: official, )) reasonReference: Condition un-encoded Dosages - Timing * Once
status:
  v: not-taken
medication: CodeableConcept
  coding:
    system:
      v: http://www.whocc.no/atc
      l: atc
    code:
      v: H02
    display:
      v: CORTICOSTEROIDS FOR SYSTEMIC USE
subject:
  l: PatientHulafe-1
  reference:
    v: Patient/PatientHulafe-1
  type:
    v: Patient
    l: Patient
reason reference:
  l: PrimaryCancerHulafe-1
  reference:
    v: Condition/PrimaryCancerHulafe-1
dosage:
  timing:
    repeat:
      bounds: Duration

ChemoHulafe-1-Ciclofosfamide-dose
type: Observation
id:
  v: ChemoHulafe-1-Ciclofosfamide-dose
meta:
  profile:
    v: http://hl7.eu/fhir/ig/pcsp/StructureDefinition/Observation-cumulativeDoseChemo-eu-pcsp
    l: Observation-cumulativeDoseChemo-eu-pcsp
text:
  status:
    v: generated
  div:
    v: Generated Narrative: Observation ChemoHulafe-1-Ciclofosfamide-dose Profile: Observation: Chemotherapy Cumulative Dose status: Final code: Cumulative dose received by a patient for a specific drug. subject: NOMBRE APELLIDO1 APELLIDO2(anonymous) Female, DoB: 2005-07-01 ( urn:oid:2.16.724.4.10.50.200#123456789 (use: official, )) value: 3000 mg/m2 (Details: UCUM codemg/m2 = 'mg/m2') method: Calculation technique
status:
  v: final
code:
  coding:
    system:
      v: http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-generic-eu-pcsp
      l: cs-generic-eu-pcsp
    code:
      v: cumulativeDose
subject:
  l: PatientHulafe-1
  reference:
    v: Patient/PatientHulafe-1
  type:
    v: Patient
    l: Patient
value: Quantity
  value:
    v: 3000
  unit:
    v: mg/m2
  system:
    v: http://unitsofmeasure.org
    l: unitsofmeasure.org
  code:
    v: mg/m2
method:
  coding: http://snomed.info/id/702873001
    system:
      v: http://snomed.info/sct
      l: sct
    code:
      v: 702873001
    display:
      v: Calculation technique

ChemoHulafe-1-Metotrexato-dose
type: Observation
id:
  v: ChemoHulafe-1-Metotrexato-dose
meta:
  profile:
    v: http://hl7.eu/fhir/ig/pcsp/StructureDefinition/Observation-cumulativeDoseChemo-eu-pcsp
    l: Observation-cumulativeDoseChemo-eu-pcsp
text:
  status:
    v: generated
  div:
    v: Generated Narrative: Observation ChemoHulafe-1-Metotrexato-dose Profile: Observation: Chemotherapy Cumulative Dose status: Final code: Cumulative dose received by a patient for a specific drug. subject: NOMBRE APELLIDO1 APELLIDO2(anonymous) Female, DoB: 2005-07-01 ( urn:oid:2.16.724.4.10.50.200#123456789 (use: official, )) value: 12000 mg/m2 (Details: UCUM codemg/m2 = 'mg/m2') method: Calculation technique
status:
  v: final
code:
  coding:
    system:
      v: http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-generic-eu-pcsp
      l: cs-generic-eu-pcsp
    code:
      v: cumulativeDose
subject:
  l: PatientHulafe-1
  reference:
    v: Patient/PatientHulafe-1
  type:
    v: Patient
    l: Patient
value: Quantity
  value:
    v: 12000
  unit:
    v: mg/m2
  system:
    v: http://unitsofmeasure.org
    l: unitsofmeasure.org
  code:
    v: mg/m2
method:
  coding: http://snomed.info/id/702873001
    system:
      v: http://snomed.info/sct
      l: sct
    code:
      v: 702873001
    display:
      v: Calculation technique

ChemoHulafe-1-Vincristina-dose
type: Observation
id:
  v: ChemoHulafe-1-Vincristina-dose
meta:
  profile:
    v: http://hl7.eu/fhir/ig/pcsp/StructureDefinition/Observation-cumulativeDoseChemo-eu-pcsp
    l: Observation-cumulativeDoseChemo-eu-pcsp
text:
  status:
    v: generated
  div:
    v: Generated Narrative: Observation ChemoHulafe-1-Vincristina-dose Profile: Observation: Chemotherapy Cumulative Dose status: Final code: Cumulative dose received by a patient for a specific drug. subject: NOMBRE APELLIDO1 APELLIDO2(anonymous) Female, DoB: 2005-07-01 ( urn:oid:2.16.724.4.10.50.200#123456789 (use: official, )) value: 5.4 mg/m2 (Details: UCUM codemg/m2 = 'mg/m2') method: Calculation technique
status:
  v: final
code:
  coding:
    system:
      v: http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-generic-eu-pcsp
      l: cs-generic-eu-pcsp
    code:
      v: cumulativeDose
subject:
  l: PatientHulafe-1
  reference:
    v: Patient/PatientHulafe-1
  type:
    v: Patient
    l: Patient
value: Quantity
  value:
    v: 5.4
  unit:
    v: mg/m2
  system:
    v: http://unitsofmeasure.org
    l: unitsofmeasure.org
  code:
    v: mg/m2
method:
  coding: http://snomed.info/id/702873001
    system:
      v: http://snomed.info/sct
      l: sct
    code:
      v: 702873001
    display:
      v: Calculation technique

ChemoHulafe-1-Citarabina-dose
type: Observation
id:
  v: ChemoHulafe-1-Citarabina-dose
meta:
  profile:
    v: http://hl7.eu/fhir/ig/pcsp/StructureDefinition/Observation-cumulativeDoseChemo-eu-pcsp
    l: Observation-cumulativeDoseChemo-eu-pcsp
text:
  status:
    v: generated
  div:
    v: Generated Narrative: Observation ChemoHulafe-1-Citarabina-dose Profile: Observation: Chemotherapy Cumulative Dose status: Final code: Cumulative dose received by a patient for a specific drug. subject: NOMBRE APELLIDO1 APELLIDO2(anonymous) Female, DoB: 2005-07-01 ( urn:oid:2.16.724.4.10.50.200#123456789 (use: official, )) value: 920 mg/m2 (Details: UCUM codemg/m2 = 'mg/m2') method: Calculation technique
status:
  v: final
code:
  coding:
    system:
      v: http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-generic-eu-pcsp
      l: cs-generic-eu-pcsp
    code:
      v: cumulativeDose
subject:
  l: PatientHulafe-1
  reference:
    v: Patient/PatientHulafe-1
  type:
    v: Patient
    l: Patient
value: Quantity
  value:
    v: 920
  unit:
    v: mg/m2
  system:
    v: http://unitsofmeasure.org
    l: unitsofmeasure.org
  code:
    v: mg/m2
method:
  coding: http://snomed.info/id/702873001
    system:
      v: http://snomed.info/sct
      l: sct
    code:
      v: 702873001
    display:
      v: Calculation technique

OrgHulafe-1
type: Organization
id:
  v: OrgHulafe-1
meta:
  profile:
    v: http://hl7.eu/fhir/ig/pcsp/StructureDefinition/Organization-center-eu-pcsp
    l: Organization-center-eu-pcsp
language:
  v: es-ES
text:
  status:
    v: generated
  div:
    v: Generated Narrative: Organization OrgHulafe-1 Language: es-ES Profile: Organization: Primary Treatment Center / Center of diagnosis active: true name: Hospital Universitari i Politècnic La Fe alias: La Fe telecom: +34 961 244 000, prensa_lafe@gva.es address: Avinguda de Fernando Abril Martorell, nº 106 Valencia Comunidad Valenciana 46026 ES (work)
active:
  v: true
name:
  v: Hospital Universitari i Politècnic La Fe
alias:
  v: La Fe
telecom:
  system:
    v: phone
  value:
    v: +34 961 244 000
telecom:
  system:
    v: email
address:
  use:
    v: work
  type:
    v: both
  line:
    v: Avinguda de Fernando Abril Martorell, nº 106
  city:
    v: Valencia
  state:
    v: Comunidad Valenciana
  postal code:
    v: 46026
  country:
    v: ES

ChemoHulafe-1-Location
type: Location
id:
  v: ChemoHulafe-1-Location
meta:
  profile:
    v: http://hl7.eu/fhir/ig/pcsp/StructureDefinition/Location-eu-pcsp
    l: Location-eu-pcsp
text:
  status:
    v: generated
  div:
    v: Generated Narrative: Location ChemoHulafe-1-Location Profile: Location: PCSP name: Hospital la Fe address: Valencia Spain
name:
  v: Hospital la Fe
address:
  city:
    v: Valencia
  country:
    v: Spain

CarePlanExample-1
type: CarePlan
id:
  v: CarePlanExample-1
meta:
  profile:
    v: http://hl7.eu/fhir/ig/pcsp/StructureDefinition/CarePlan-eu-pcsp
    l: CarePlan-eu-pcsp
text:
  status:
    v: additional
  div:
    v: FOLLOW-UP RECOMMENDATIONS Here below are listed personalized follow-up recommendations, based on the treatments you received. These advices are based on international experience with people who received similar treatments as you. They are meant to prevent and/or diagnose at an early stage possible future complications. It is possible that over time these recommendations will be updated according to new clinical situations and/or new data in the scientific literature. We will make all possible efforts in order to update about any new update. We encourage you to report to your doctor any persistent symptom you might have, in order to allow an early identification of its cause. <!-- --> General recommendations A healthy lifestyle helps to maintain physical and mental wellbeing, as well as preventing possible diseases such as cardiovascular complications, tumors, and psychological problems. We therefore recommend you to: Maintain a normal body weight and engage in regular physical activity. Eat plenty of fruits and vegetables, and reduce fat, sugar, and salt intake. Don't smoke and avoid excessive alcohol intake. Maintain proper dental hygiene. Avoid excessive sun exposure and remember to use high-protection sunscreen. Check your blood pressure periodically. Report to your health care provider any experience of chronic pain, excessive fatigue and/or deterioration of performance in your daily activities (study, work and/or exercise). Adhere to all cancer screening programs that will be offered by the health system. <!-- --> You might be at risk of Because you were treated with We therefore recommend you to Subsequent thyroid cancer RT to a vol exposing the thyroid gland Counselling regarding the increased risk for developing differentiated thyroid to inform their HCP if they detect a thyroid mass (independent of the presence or absence of associated symptoms), every 5 years - Physical examination of the neck as part of a complete physical examination, whenever a survivor…
status:
  v: draft
intent:
  v: proposal
subject:
  l: PatientHulafe-1
  reference:
    v: Patient/PatientHulafe-1
  display:
    v: APELLIDO1
period:
  start:
    v: 2022-05-17
created:
  v: 2022-05-12
addresses:
  l: PrimaryCancerHulafe-1
  reference:
    v: Condition/PrimaryCancerHulafe-1
  display:
    v: Carcinoma tiroides
activity:
  detail:
    reason reference:
      l: ObservationRiskFactor-2
      reference:
        v: Observation/ObservationRiskFactor-2
      display:
        v: RT >= 10 Gy to a vol exposing the breasts
    status:
      v: not-started
    description:
      v: A healthy lifestyle helps to maintain physical and mental wellbeing, as well as preventing possible diseases such as cardiovascular complications, tumors, and psychological problems. We therefore recommend you to: (1) Maintain a normal body weight and engage in regular physical activity. (2) Eat plenty of fruits and vegetables, and reduce fat, sugar, and salt intake. (3) Don't smoke and avoid excessive alcohol intake. (4) Maintain proper dental hygiene. (5) Avoid excessive sun exposure and remember to use high-protection sunscreen.(6) Check your blood pressure periodically. (7) Report to your health care provider any experience of chronic pain, excessive fatigue and/or deterioration of performance in your daily activities (study, work and/or exercise). (8) Adhere to all cancer screening programs that will be offered by the health system.
activity:
  detail:
    reason reference:
      l: ObservationRiskFactor-1
      reference:
        v: Observation/ObservationRiskFactor-1
      display:
        v: RT to a vol exposing the thyroid gland
    status:
      v: not-started
    description:
      v: Counselling regarding the increased risk for developing differentiated thyroid to inform their HCP if they detect a thyroid mass (independent of the presence or absence of associated symptoms), every 5 years - Physical examination of the neck as part of a complete physical examination, whenever a survivor is assessed by a HCP - Counselling regarding options for differentiated thyroid carcinoma surveillance, at least every 5 years If the decision to commence surveillance is made, make a shared decision for one of these two surveillance modalities: - Neck palpation, every 1-2 years, starting 5 years after radiotherapy, or - Thyroid ultrasonographyw, every 3-5 years, starting 5 years after radiotherapy
activity:
  detail:
    reason reference:
      l: ObservationRiskFactor-2
      reference:
        v: Observation/ObservationRiskFactor-2
      display:
        v: RT >= 10 Gy to a vol exposing the breasts
    status:
      v: not-started
    description:
      v: Mammography and breast MRI every year if ≥ 25 years of age or ≥ 8 years from radiation, whichever occurs last
activity:
  detail:
    reason reference:
      l: ObservationRiskFactor-3
      reference:
        v: Observation/ObservationRiskFactor-3
      display:
        v: RT >= 35 Gy to a vol exposing the heart
    reason reference:
      l: ObservationRiskFactor-4
      reference:
        v: Observation/ObservationRiskFactor-4
      display:
        v: Anthracyclines (doxorubicin isotoxic equivalents)>= 250 mg/m2
    status:
      v: not-started
    description:
      v: A physical cardiac examination at every LTFU visit, at least every 5 years. Screening for modifiable cardiovascular risk factors (hypertension, diabetes, dyslipidaemia, obesity, smoking and low levels of physical activity). - ECG once at entry into LTFU. Repeat ECG once after the age of 18 years if entry into LTFU was at a younger age. - Echocardiogram with specific attention to left ventricular systolic function, to valvular structure and function and to the pericardium, starting 2 years after treatment and at least every 2-3 years; Echocardiogram with specific attention to left ventricular function, prior to pregnancy or in the first trimester, if female - Refer to a cardiologist if an abnormal ejection fraction or if other abnormalities are identified - Refer for interventions to help avert the risk of symptomatic cardiomyopathy if modifiable cardiovascular risk factors are identified Refer to a cardiologist if an abnormal ejection fraction or if other abnormalities are identified - Refer for interventions to help avert the risk of symptomatic cardiomyopathy if modifiable cardiovascular risk factors are identified

ObservationRiskFactor-1
type: Observation
id:
  v: ObservationRiskFactor-1
meta:
  profile:
    v: http://hl7.eu/fhir/ig/pcsp/StructureDefinition/Observation-riskfactor-eu-pcsp
    l: Observation-riskfactor-eu-pcsp
text:
  status:
    v: generated
  div:
    v: Generated Narrative: Observation ObservationRiskFactor-1 Profile: Observation: Risk Factor status: Final code: Risk factor subject: APELLIDO1 effective: 2022-05-12 --> (ongoing) value: RT to a vol exposing the thyroid gland
status:
  v: final
code:
  coding: http://snomed.info/id/80943009
    system:
      v: http://snomed.info/sct
      l: sct
    code:
      v: 80943009
    display:
      v: Risk factor
subject:
  l: PatientHulafe-1
  reference:
    v: Patient/PatientHulafe-1
  display:
    v: APELLIDO1
effective: Period
  start:
    v: 2022-05-12
value: CodeableConcept
  coding:
    system:
      v: http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp
      l: cs-riskfactor-eu-pcsp
    code:
      v: 1.1
    display:
      v: RT to a vol exposing the thyroid gland

ObservationRiskFactor-2
type: Observation
id:
  v: ObservationRiskFactor-2
meta:
  profile:
    v: http://hl7.eu/fhir/ig/pcsp/StructureDefinition/Observation-riskfactor-eu-pcsp
    l: Observation-riskfactor-eu-pcsp
text:
  status:
    v: generated
  div:
    v: Generated Narrative: Observation ObservationRiskFactor-2 Profile: Observation: Risk Factor status: Final code: Risk factor subject: APELLIDO1 effective: 2022-05-12 --> (ongoing) value: RT >= 10 Gy to a vol exposing the breasts
status:
  v: final
code:
  coding: http://snomed.info/id/80943009
    system:
      v: http://snomed.info/sct
      l: sct
    code:
      v: 80943009
    display:
      v: Risk factor
subject:
  l: PatientHulafe-1
  reference:
    v: Patient/PatientHulafe-1
  display:
    v: APELLIDO1
effective: Period
  start:
    v: 2022-05-12
value: CodeableConcept
  coding:
    system:
      v: http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp
      l: cs-riskfactor-eu-pcsp
    code:
      v: 2.1
    display:
      v: RT >= 10 Gy to a vol exposing the breasts

ObservationRiskFactor-3
type: Observation
id:
  v: ObservationRiskFactor-3
meta:
  profile:
    v: http://hl7.eu/fhir/ig/pcsp/StructureDefinition/Observation-riskfactor-eu-pcsp
    l: Observation-riskfactor-eu-pcsp
text:
  status:
    v: generated
  div:
    v: Generated Narrative: Observation ObservationRiskFactor-3 Profile: Observation: Risk Factor status: Final code: Risk factor subject: APELLIDO1 effective: 2022-05-12 --> (ongoing) value: RT >= 35 Gy to a vol exposing the heart
status:
  v: final
code:
  coding: http://snomed.info/id/80943009
    system:
      v: http://snomed.info/sct
      l: sct
    code:
      v: 80943009
    display:
      v: Risk factor
subject:
  l: PatientHulafe-1
  reference:
    v: Patient/PatientHulafe-1
  display:
    v: APELLIDO1
effective: Period
  start:
    v: 2022-05-12
value: CodeableConcept
  coding:
    system:
      v: http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp
      l: cs-riskfactor-eu-pcsp
    code:
      v: 3.1
    display:
      v: RT >= 35 Gy to a vol exposing the heart

ObservationRiskFactor-4
type: Observation
id:
  v: ObservationRiskFactor-4
meta:
  profile:
    v: http://hl7.eu/fhir/ig/pcsp/StructureDefinition/Observation-riskfactor-eu-pcsp
    l: Observation-riskfactor-eu-pcsp
text:
  status:
    v: generated
  div:
    v: Generated Narrative: Observation ObservationRiskFactor-4 Profile: Observation: Risk Factor status: Final code: Risk factor subject: APELLIDO1 effective: 2022-05-12 --> (ongoing) value: Anthracyclines (doxorubicin isotoxic equivalents)>= 250 mg/m2
status:
  v: final
code:
  coding: http://snomed.info/id/80943009
    system:
      v: http://snomed.info/sct
      l: sct
    code:
      v: 80943009
    display:
      v: Risk factor
subject:
  l: PatientHulafe-1
  reference:
    v: Patient/PatientHulafe-1
  display:
    v: APELLIDO1
effective: Period
  start:
    v: 2022-05-12
value: CodeableConcept
  coding:
    system:
      v: http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp
      l: cs-riskfactor-eu-pcsp
    code:
      v: 3.2
    display:
      v: Anthracyclines (doxorubicin isotoxic equivalents)>= 250 mg/m2

DocumentReferenceExample-1
type: DocumentReference
id:
  v: DocumentReferenceExample-1
meta:
  profile:
    v: http://hl7.eu/fhir/ig/pcsp/StructureDefinition/DocumentReference-eu-pcsp
    l: DocumentReference-eu-pcsp
text:
  status:
    v: generated
  div:
    v: Generated Narrative: DocumentReference DocumentReferenceExample-1 Profile: DocumentReference: PCSP status: Current docStatus: Preliminary type: Childhood Cancer Survivor Passport subject: APELLIDO1 date: 2022-06-14 13:28:17+0200 content Attachments - ContentType Language Data Title Creation * application/pdf Spanish (Region=Spain) (base64 data - 251,792 base64 chars) Survivor Passport of APELLIDO1 2022-06-14
status:
  v: current
doc status:
  v: preliminary
type:
  coding:
    system:
      v: http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-generic-eu-pcsp
      l: cs-generic-eu-pcsp
    code:
      v: surpass
    display:
      v: Childhood Cancer Survivor Passport
subject:
  l: PatientHulafe-1
  reference:
    v: Patient/PatientHulafe-1
  display:
    v: APELLIDO1
date:
  v: 2022-06-14T13:28:17+02:00
content:
  attachment:
    content type:
      v: application/pdf
    language:
      v: es-ES
    title:
      v: Survivor Passport of APELLIDO1
    creation:
      v: 2022-06-14

v: 11486-8

v: NA

v: Not Applicable

v: 4

v: >

v: w

v: w

v: 2

v: Perform Mammography and Breast magnetic resonance imaging (MRI) should be performed annually from the eighth year after the end of radiotherapy, but not before the age of 25. These examinations should be continued until at least age 60.

v: 2

v: Subsequent breast cancer

v: 1

v: Perform appropriate thyroid screening from the fifth year after the end of radiotherapy. Discuss with your doctor whether to schedule: Clinical thyroid examination every 1-2 years; or Thyroid ultrasound every 3-5 years.

v: 1

v: Subsequent thyroid cancer

v: 2

v: Perform Mammography and Breast magnetic resonance imaging (MRI) should be performed annually from the eighth year after the end of radiotherapy, but not before the age of 25. These examinations should be continued until at least age 60.

v: 2

v: Subsequent breast cancer

v: 3

v: Perform: Cardiological evaluation at the end of treatment and every 2-3 years thereafter; Electrocardiogram (ECG) at the end of treatment, to be repeated at the age of 18 and cardiological evaluation in case of palpitations, dizziness and/or fainting/loss of consciousness. Echocardiogram 2 years after the end of treatment, to be repeated every 2-3 years; If female, echocardiogram in the first trimester of pregnancy.

v: 3

v: Cardiac problems (Cardiomyopathy and/or Valvular disease and/or Cardiac ischemia)